Adelaide scientists make HIV a safe aid in gene therapy

November 19, 2001

Viruses have evolved , over thousands of years, to overcome our bodies' defenses against viral infection. Once they gain a hold in our bodies, viruses can skillfully transfer their genetic material into our cells, combining it with our own genetic material and causing infection.

Many human diseases result from missing or damaged genes in our cells. Such abnormal or missing genes can potentially be replaced by 'normal' genes using the technique of 'Gene Therapy', thus overcoming the disease.

Senior researcher Dr Don Anson and PhD student Maria Fuller from the Women's and Children's Hospital, Adelaide have today published a paper in Human Gene Therapy in which they have shown that Human Immunodeficiency Virus Type 1 (HIV-1), after modification can be safely used to transfer therapeutic genes into human cells without transferring the disease.

"Viruses are very good at transferring their genetic material into cells, so it is logical to use them to carry any therapeutic genes we want to get into those same cells. HIV-1 is particular suited to this purpose, because, firstly, the genetic material transferred becomes a permanent part of the host cell, and secondly because it transfers genetic material to cells that are not growing and not all viruses can do this - and it is these non growing cells that we need to target with therapeutic genes," Dr Anson says.

"However to use HIV-1 for this purpose we must be sure it cannot infect our cells and cause AIDS. We are now able to modify HIV's genetic material so those viral proteins essential for it to reproduce and cause disease in our cells are removed."

Other groups worldwide have also been working on gene transfer using HIV-1, but Dr Anson's group has developed a method to vastly increase the safety with which HIV-1 can be used to transfer genes without causing disease.

Currently animal models of genetic disease are being studied using this approach before the methods can be taken to trials of human disease.

The use of this HIV-1 transfer approach has wide applicability for a variety of human genetic diseases.
This work was supported by the National Health and Medical Research Council.

To arrange interviews with Dr Anson please contact:
Dr Edna Bates
Manager, Research Communications
* ( 618) 8161 7388
Ms Chris Ostermann
Director of Media and Community Relations
* mobile 0401 125 630 (after hours)
Women's and Children's Hospital

Women's and Children's Hospital, Adelaide - Part of the Children, Youth and Women's Health Service

Related Gene Therapy Articles from Brightsurf:

Risk of AAV mobilization in gene therapy
New data highlight safety concerns for the replication of recombinant adeno-associated viral (rAAV) vectors commonly used in gene therapy.

Discovery challenges the foundations of gene therapy
An article published today in Science Translational Medicine by scientists from Children's Medical Research Institute has challenged one of the foundations of the gene therapy field and will help to improve strategies for treating serious genetic disorders of the liver.

Gene therapy: Novel targets come into view
Retinitis pigmentosa is the most prevalent form of congenital blindness.

Gene therapy targets inner retina to combat blindness
Batten disease is a group of fatal, inherited lysosomal storage disorders that predominantly affect children.

New Human Gene Therapy editorial: Concern following gene therapy adverse events
Response to the recent report of the deaths of two children receiving high doses of a gene therapy vector (AAV8) in a Phase I trial for X-linked myotubular myopathy (MTM).

Restoring vision by gene therapy
Latest scientific findings give hope for people with incurable retinal degeneration.

Gene therapy/gene editing combo could offer hope for some genetic disorders
A hybrid approach that combines elements of gene therapy with gene editing converted an experimental model of a rare genetic disease into a milder form, significantly enhancing survival, shows a multi-institutional study led by the University of Pennsylvania and Children's National Hospital in Washington, D.C.

New technology allows control of gene therapy doses
Scientists at Scripps Research in Jupiter have developed a special molecular switch that could be embedded into gene therapies to allow doctors to control dosing.

Gene therapy: Development of new DNA transporters
Scientists at the Institute of Pharmacy at Martin Luther University Halle-Wittenberg (MLU) have developed new delivery vehicles for future gene therapies.

Gene therapy promotes nerve regeneration
Researchers from the Netherlands Institute for Neuroscience and the Leiden University Medical Center have shown that treatment using gene therapy leads to a faster recovery after nerve damage.

Read More: Gene Therapy News and Gene Therapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to